Travere Therapeutics (TVTX) Gross Margin (2014 - 2026)

Travere Therapeutics has reported Gross Margin for 13 years, with the latest figure at 80.49% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 431.0% year-over-year to 80.49%; the trailing twelve-month figure through Mar 2026 stood at 143.48% (up 5030.0% YoY), and the FY2025 full-year result was 11.17%, down 10785.0% from the prior year.
• Gross Margin for Q1 2026 stood at 80.49%, down from 100.73% in the prior quarter.
• The five-year high for Gross Margin was 100.73% in Q4 2025, with the low at 80.49% in Q1 2026.
• Historically, Gross Margin has averaged 93.68% across 5 years, with a median of 96.04% in 2025.
• Annual changes were most pronounced in 2024 — Gross Margin soared 978 bps — and 2025, when it slumped 1157 bps.
• Travere Therapeutics' Gross Margin stood at 97.04% in 2022, then fell by 7 bps to 89.87% in 2023, then gained by 7 bps to 96.59% in 2024, then increased by 4 bps to 100.73% in 2025, then declined by 20 bps to 80.49% in 2026.
• The last three Gross Margin figures came in at 80.49% (Q1 2026), 100.73% (Q4 2025), and 96.04% (Q3 2025), per Business Quant data.